Original Article

Design of A Potential Multi-Epitope Vaccine against Toxoplasma gondii Based on Microneme Proteins Using A Comprehensive Immunoinformatics Approach

Abstract

Background: Toxoplasma gondii (T. gondii) is an intracellular apicomplexan parasite responsible for toxoplasmosis in humans and animals worldwide. Despite its high prevalence, no effective vaccine is currently available for human use. This study aimed to design and evaluate a multi-epitope vaccine candidate based on T. gondii microneme proteins (MIC2, MIC3, MIC4, MIC6, MIC8, and MIC13) using immunoinformatics approaches.
Methods: B-cell, cytotoxic T-lymphocyte (CTL), and helper T-lymphocyte (HTL) epitopes were predicted and screened based on their antigenicity, allergenicity, toxicity, and immunogenicity. Selected epitopes were linked using appropriate peptide linkers and fused with the 50S ribosomal protein L7/L12 adjuvant. The construct was further assessed for physicochemical properties, structural features, antigenicity, allergenicity, solubility, immune responses, and codon optimization.
Results: The final vaccine construct consisted of 624 amino acids with a predicted molecular weight of 64.97 kDa. The vaccine was predicted to be antigenic, stable, soluble, and non-allergenic. Structural analyses supported the quality of the refined model. Immune simulation indicated the induction of strong humoral and cellular immune responses, including enhanced antibody production and T-cell activation.
Conclusion: The designed multi-epitope vaccine demonstrated promising immunological and physicochemical characteristics.

1. Dubey JP. Toxoplasmosis of animals and humans: CRC press; 2016.
2. Montoya J, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363: 1965–76.
3. Teimouri A, Goudarzi F, Goudarzi K, et al. Toxoplasma gondii infection in immunocompromised patients in Iran (2013–2022): a systematic review and meta-analysis. Iran J Parasitol. 2022;17(4):443-457.
4. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12-13):1217-58.
5. Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31(4):e 00057-17.
6. Dubey JP. History of the discovery of the life cycle of Toxoplasma gondii. Int J Parasitol. 2009;39(8):877-82.
7. Lim SS-Y, Othman RY. Recent advances in Toxoplasma gondii immunotherapeutics. Korean J Parasitol. 2014;52(6):581-93.
8. Cong H, Mui EJ, Witola WH, et al. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A* 1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+ T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010; 6:12.
9. Ferra B, Holec-Gąsior L, Grąźlewska W. Toxoplasma gondii recombinant antigens in the serodiagnosis of toxoplasmosis in domestic and farm animals. Animals (Basel). 2020;10(8):1245.
10. Naghi Vishteh M, Javadi Mamaghani A, Rashidi S, et al. Peptide-based monoclonal antibody production against SAG1 (P30) protein of Toxoplasma gondii. Monoclon Antib Immunodiagn Immunother. 2020;39(2):51-6.
11. Wang S, Zhang Z, Wang Y, et al. Toxoplasma gondii excretory/secretory antigens (TgESAs) suppress pro-inflammatory cytokine secretion by inhibiting TLR-induced NF-κB activation in LPS-stimulated murine macrophages. Oncotarget. 2017;8(51):88351-88359.
12. Wang Y, Yin H. Research advances in microneme protein 3 of Toxoplasma gondii. Parasit Vectors. 2015; 8: 384.
13. Kessler H, Herm-Götz A, Hegge S, et al. Microneme protein 8–a new essential invasion factor in Toxoplasma gondii. J Cell Sci. 2008;121(Pt 7):947-56.
14. Sheiner L, Santos JM, Klages N, et al. Toxoplasma gondii transmembrane microneme proteins and their modular design. Mol Microbiol. 2010;77(4):912-29.
15. Cérède O, Dubremetz JF, Soête M, et al. Synergistic role of micronemal proteins in Toxoplasma gondii virulence. J Exp Med. 2005;201(3):453-63.
16. Wang Y, Yin H. Research advances in microneme protein 3 of Toxoplasma gondii. Parasit Vectors. 2015; 8:384.
17. Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics. 2014;30(6):846-51.
18. Gupta S, Kapoor P, Chaudhary K, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957.
19. Larsen MV, Lundegaard C, Lamberth K, et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 2007; 8:424.
20. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007; 8 :4.
21. Calis JJ, Maybeno M, Greenbaum JA, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013;9(10):e1003266.
22. Bui H-H, Sidney J, Dinh K, et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics. 2006;7:153.
23. Hammed-Akanmu M, Mim M, Osman AY, et al. Designing a multi-epitope vaccine against Toxoplasma gondii: an immunoinformatics approach. Vaccines (Basel). 2022;10(9):1389.
24. Ghaffari AD, Dalimi A, Ghaffarifar F, Pirestani M. Antigenic properties of dense granule antigen 12 protein using bioinformatics tools in order to improve vaccine design against Toxoplasma gondii. Clin Exp Vaccine Res. 2020;9(2):81-96.
25. Foroutan M, Ghaffari AD, Soltani S, et al. Bioinformatics analysis of calcium-dependent protein kinase 4 (CDPK4) as Toxoplasma gondii vaccine target. BMC Res Notes. 2021;14(1):50.
26. Peng J, Xu J. RaptorX: exploiting structure information for protein alignment by statistical inference. Proteins. 2011; 79 Suppl 10(Suppl 10):161-71.
27. Heo L, Park H, Seok C. GalaxyRefine: Protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 2013; 41(Web Server issue):W384-8.
28. Ponomarenko J, Bui H-H, Li W, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008; 9:514.
29. Kumar P, Kumar P, Shrivastava A, et al. Immunoinformatics-based multi-epitope containing fused polypeptide vaccine design against visceral leishmaniasis with high immunogenicity and TLR binding. Int J Biol Macromol. 2023; 253(Pt 8):127567.
30. Dodangeh S, Daryani A, Sharif M, et al. A systematic review on efficiency of microneme proteins to induce protective immunity against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 2019;38(4):617-29.
31. Naveed M, Yaseen AR, Khalid H, et al. Execution and design of an anti HPIV-1 vaccine with multiple epitopes triggering innate and adaptive immune responses: an immunoinformatic approach. Vaccines (Basel). 2022;10(6):869.
32. Shamriz S, Ofoghi H, Moazami N. Effect of linker length and residues on the structure and stability of a fusion protein with malaria vaccine application. Comput Biol Med. 2016;76:24-9.
33. Laskowski RA, Jabłońska J, Pravda L, Vařeková RS, Thornton JM. PDBsum: Structural summaries of PDB entries. Protein Sci. 2018;27(1):129-34.
34. Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15(2):51-7.
35. Chen X, Zaro JL, Shen W-C. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013;65(10):1357-69.
36. Selseleh M, Keshavarz H, Mohebali M, et al. Production and evaluation of Toxoplasma gondii recombinant GRA7 for serodiagnosis of human infections. Korean J Parasitol. 2012;50(3):233-8.
37. Abasi E, Khademvatan S, Shojaee S, et al. Assessment of immunogenicity of multi-epitope DNA vaccine encoding CDPK3, Rop22 & MIC8 of Toxoplasma gondii adjuvanted with IL-12 against acute and chronic toxoplasmosis in BALB/c mice. Iran J Parasitol. 2026; 21(1):11-22.
38. Mavi SA, Modarressi MH, Mohebali M, et al. Assessment of the immunogenicity and protective efficiency of a novel dual-promoter DNA vaccine, harboring SAG1 and GRA7 genes, from RH strain of Toxoplasma gondii in BALB/c mice. Infect Drug Resist. 2019; 12:2519-2530.
Files
IssueVol 21 No 4 (2026) QRcode
SectionOriginal Article(s)
Keywords
Toxoplasma gondii Immunoinformatics Multi-epitope vaccine Microneme proteins

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Paknejad N, Dalir Ghaffari A, Khadem Mohammadi M. Design of A Potential Multi-Epitope Vaccine against Toxoplasma gondii Based on Microneme Proteins Using A Comprehensive Immunoinformatics Approach. Iran J Parasitol. 2026;21(4):445-456.